Atossa Therapeutics (ATOS) announced that the United States Patent and Trademark Office has granted a new patent directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations. The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additional support for Atossa’s intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, a potent Selective Estrogen Receptor Modulator.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.